|By Marketwired .||
|June 30, 2014 04:15 PM EDT||
NEW YORK, NY -- (Marketwired) -- 06/30/14 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS) securities between February 25, 2013 and September 10, 2013.
For more information, click here: http://zlk.9nl.com/ovascience.
The complaint alleges that defendants made materially false and misleading statements regarding the Company's business and operations. In particular, OvaScience represented to investors and the Food and Drug Administration that its fertility treatment AUGMENT would likely qualify for designation as a 361 HCT/P, which allows human cellular and tissue based products to be tested and marketed without FDA licensure.
On September 10, 2013, the Company disclosed the receipt of a letter from the FDA in which the status of AUGMENT as a 361 HCT/P was questioned. The FDA also requested that OvaScience file an Investigational New Drug (IND) application, thus ensuring that the drug face mandatory clinical testing.
If you suffered a loss in OvaScience you have until August 5, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ovascience.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
Dec. 4, 2016 03:00 PM EST Reads: 3,240
Dec. 4, 2016 03:00 PM EST Reads: 2,510
Dec. 4, 2016 02:15 PM EST Reads: 1,984
Dec. 4, 2016 02:00 PM EST Reads: 904
Dec. 4, 2016 02:00 PM EST Reads: 1,896
Dec. 4, 2016 02:00 PM EST Reads: 559
Dec. 4, 2016 01:45 PM EST Reads: 2,153
Dec. 4, 2016 01:30 PM EST Reads: 1,533
Dec. 4, 2016 01:15 PM EST Reads: 618
Dec. 4, 2016 01:00 PM EST Reads: 756
Dec. 4, 2016 12:45 PM EST Reads: 2,122
Dec. 4, 2016 12:30 PM EST Reads: 1,671
Dec. 4, 2016 12:00 PM EST Reads: 772
Dec. 4, 2016 11:45 AM EST Reads: 377
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Dec. 4, 2016 11:15 AM EST Reads: 902